Today's Research Report Coverage on Medical Research Stocks -- DexCom, Agilent Technologies, Quintiles IMS, and Thermo Fisher Scientific

Tuesday, October 24, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 24, 2017 /PRNewswire/ --

If you want a Stock Review on DXCM, A, Q, or TMO then come over to

and sign up for your free customized report. For today, research coverage has been initiated by on DexCom Inc. (NASDAQ: DXCM), Agilent Technologies Inc. (NYSE: A), Quintiles IMS Holdings Inc. (NYSE: Q), and Thermo Fisher Scientific
Inc. (NYSE: TMO). Companies in the Medical Laboratories and Research group focus on performing various tests on patients that give them information on patients' health. These firms, as a whole, tend to offer higher dividend yields than the wider Healthcare sector. Learn more about these stocks by signing up for their free reports on at:


On Monday, shares in San Diego, California headquartered DexCom Inc. recorded a trading volume of 1.70 million shares. The stock ended the session 0.02% lower at $44.77. The Company's shares are trading 29.72% below their 50-day moving average. Moreover, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have a Relative Strength Index (RSI) of 21.43.

On September 28th, 2017, research firm Wedbush reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $85 a share to $76 a share.

On October 10th, 2017, DexCom announced plans to release its Q3 2017 financial results after market close on November 01st, 2017. Management will hold a conference call at 4:30 p.m. ET that same day to review the Company's performance. The call will be concurrently webcast and available on the Company's website. The free research report on DXCM is available at:

Agilent Technologies 

Santa Clara, California headquartered Agilent Technologies Inc.'s stock closed the day 0.34% lower at $67.02 with a total trading volume of 1.27 million shares. The Company's shares have advanced 1.89% in the past month, 10.70% in the previous three months, and 47.10% since the start of this year. The stock is trading 3.70% and 16.58% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Agilent Technologies have an RSI of 62.01.

On September 26th, 2017, research firm Goldman resumed its 'Neutral' rating on the Company's stock, with a target price of $68 per share.

On October 17th, 2017 at the American Society for Human Genetics Conference in Orlando, Florida, Agilent Technologies announced the first expansion of the SureGuide pooled CRISPR libraries for functional genomics, offering pooled libraries for CRISPR activation and interference. Every SureGuide CRISPR library is synthesized using the Company's advanced SurePrint DNA synthesis platform, simultaneously printing billions of DNA bases with industry-leading sequence fidelity and superior representation. The complimentary report on A can be downloaded at:

Quintiles IMS Holdings 

Shares in Durham, North Carolina headquartered Quintiles IMS Holdings Inc. recorded a trading volume of 1.48 million shares. The stock ended yesterday's trading session 0.84% lower at $102.16. The Company's shares have advanced 7.88% in the past month, 12.86% in the previous three months, and 34.33% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.72% and 18.56%, respectively. Furthermore, shares of Quintiles IMS, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have an RSI of 72.95.

On October 12th, 2017, Quintiles IMS announced that it will release its Q3 2017 financial results pre-market on October 26th, 2017. The Company's management team will host a conference call and webcast at 9:00 a.m. ET that same day. The earnings release and accompanying financial information will be posted on the Company's Investor Relations website. Visit us today and download our complete research report on Q for free at:

Thermo Fisher Scientific 

Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc.'s stock finished Monday's session 0.26% higher at $194.37 with a total trading volume of 1.31 million shares. The Company's shares have advanced 3.22% in the last one month, 7.91% over the previous three months, and 37.75% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.23% and 14.62%, respectively. Additionally, shares of the Company, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide, have an RSI of 64.38.

On September 28th, 2017, Thermo Fisher Scientific announced that it will release its financial results for Q3 pre-market on October 25th, 2017, and will hold a conference call that same day at 8:30 a.m. EDT. During the call, the Company will discuss its financial performance as well as future expectations. The live call may be accessed under the "Investors" section of the Company's website. Get free access to your technical report on TMO at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store